All In Biotech

Drug Trial Radar · NCT06964776

A Study of LY4268989 (MORF-057) in Healthy Participants

A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

May 1, 2025

Primary completion

Feb 17, 2026

Study completion Feb 17, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants

Conditions

  • Healthy

Interventions

  • LY4268989Drug

    Administered orally

  • PlaceboDrug

    Administered placebo

  • MidazolamDrug

    Administered orally

  • MidazolamDrug

    Administered intravenously (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5)Time frame: Day 1 to Day 17
  2. PK: Area Under the Concentration Curve (AUC) of LY4268989 (Cohort 1) and (Cohort 5)Time frame: Day 1 to Day 17
  3. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Cohort 1), (Cohort 3), and (Cohort 5)Time frame: Baseline to Study Completion (Up to Day 17)
  4. Number of Participants with TEAEs and SAEs (Cohort 4)Time frame: Baseline to Study Completion (Up to Period 4, Day 4)
  5. PK: Cmax of LY4268989 (Cohort 2)Time frame: Day 1 to Day 13
  6. PK: AUC of LY4268989 (Cohort 2)Time frame: Day 1 to Day 13
  7. PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 3)Time frame: Day 1 to Day 17
  8. PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 8)Time frame: Day 3 and Day 11
  9. PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 3)Time frame: Day 1 to Day 17
  10. PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 8)Time frame: Day 3 to Day 11
  11. PK: Cmax of LY4268989 (Cohort 6)Time frame: Day 1 to Day 7
  12. PK: AUC of LY4268989 (Cohort 6)Time frame: Day 1 to Day 7
  13. PK: Cmax of LY4268989 (Cohort 7)Time frame: Day 1 to Day 12
  14. PK: AUC of LY4268989 (Cohort 7)Time frame: Day 1 to Day 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CenExel ACT

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.